Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study*
|
|
- Roberta Tucker
- 5 years ago
- Views:
Transcription
1 .. FERTILITY AND STERILITY Copyright 99 The American Fertility Society Vol. 59, No., March 99 Printed on acid-free paper in U.S.A. Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study* Luigi Fedele, M.D. t Stefano Bianchi, M.D. Luca Bocciolone, M.D. Giuliana Di Nola, M.D. Dorella Franchi, M.D. Istituto Ostetrico-Ginecologico "L. Mangiagalli," Universitri Milano, Italy Objective: To evaluate the changes of pain symptoms induced by buserelin acetate, a gonadotropin-releasing hormone agonist, in a group of patients with endometriosis. Design: Thirty-five infertile patients with one or more of the following symptoms (dysmenorrhea, pelvic pain, deep dyspareunia, and endometriosis stage I or II) were allocated randomly to treatment with buserelin acetate, tlg/d IN for 6 months (n = 9) or expectant management (n = 6). Pain symptoms were recorded by the women themselves using a questionnaire that included two s for pain evaluation: one analogue and one multidimensional. The treated and untreated patients were followed for a minimum of 8 and months from the time of randomization, respectively. Results: Buserelin acetate markedly reduced dysmenorrhea, pelvic pain, and dyspareunia during the treatment and also for the subsequent months. During follow-up of the expectant management group, dysmenorrhea resolved in 9% (/6) of the cases, and pelvic pain did not recur after diagnostic laparoscopy in one of the three women affected nor did deep dyspareunia in two of the five who reported the symptom before laparoscopy. Conclusion: Buserelin acetate induced a significant improvement of pain symptoms that persisted in approximately half of the patients even after withdrawal of the drug. However, symptoms associated with endometriosis showed a spontaneous remission in approximately one fifth of the untreated patients. Fertil Steril 99;59:56- Key Words: Endometriosis, pelvic pain, buserelin acetate Endometriosis is frequently associated with pain symptoms that may constitute the patient's only or main disturbance also in initial stages of the disease, In the minimal and mild stages of the revised American Fertility Society (AFS) classification () dysmenorrhea is reported in approximately 7% of the patients and intermenstrual pelvic pain and deep dyspareunia in approximately 5% (). Medical treatment has been widely used for minimal and mild endometriosis in the last decade, first with danazol, Received March 6, 99; revised and accepted November 7, 99. * Project "Studio territoriale multicentrico della malattia endometriosica" supported by Ministero della Sanita, Rome, Italy. t Reprint requests: Luigi Fedele, M.D., Istituto Ostetrico Ginecologico "L. Mangiagalli," Universita di Milano, via Commenda, Milano, Italy. then with gestrinone, and last with gonadotropinreleasing hormone agonists (GnRH-a). Numerous studies have demonstrated the efficacy of these drugs in inducing pain resolution during their administration, associated with more or less important side effects according to the agent used (for review see Metzger and Luciano []). Whether pain relief persists after the end of treatment is still uncertain. Initial observations revealed a recurrence of symptoms in a large proportion of patients (4, 5). However, the exact frequency and characteristics of symptoms recurrence are unknown, as is the evolution of pain symptoms in untreated patients. The aim of the present study was to analyze the presence and severity of pain symptoms during and after therapy with buserelin acetate, a GnRH -a, in a group of infertile patients with minimal or mild endometriosis compared with an untreated group. 56 Fedele et al. Buserelin acetate for endometriosis Fertility and Sterility
2 4 Patients MATERIALS AND METHODS The present series consisted of all women with one or more of the following symptoms (dysmenorrhea, pelvic pain, and deep dyspareunia) enrolled at our institute in a multicenter randomized study that compared the efficacy of buserelin acetate with that of expectant management in the treatment of infertility associated with endometriosis stage I or II of the revised AFS classification (6). Nineteen patients were allocated to treatment with buserelin acetate, ~g/d IN for 6 months and 6 to expectant management. No therapeutic maneuver was performed at the time of the diagnostic laparoscopy, which was always combined with a dilatation and curettage (D and C). Before laparoscopy all the women completed a questionnaire on the presence and severity of dysmenorrhea and pelvic pain and the presence of deep dyspareunia (Table ). The severity of dysmenorrhea and pelvic pain was evaluated according to two s. One was multidimensional and considered any limitation of daily activities, the coexistence of systemic symptoms, and the necessity of analgesics. Scores of to, 4 to 5, and 6 to 7 defined, respectively, mild, moderate, and severe pain. In the other, a linear one, pain severity was scored from to, with indicating the absence of pain and scores of to 4, 5 to 7, and 8 to as mild, moderate, and severe pain, respectively. The same questionnaire was compiled every month for 8 months in the treated patients and months in those untreated unless pregnancy occurred or the patients were switched to another treatment. The questionnaires were evaluated every 4 months at follow-up visits. Data Analysis We calculated the cumulative proportion of women with recurrence of dysmenorrhea according to treatment allocation using the actuarial method, and the curves were compared by the log-rank test (7). The actuarial method allows comparison of women with different lengths of follow-up. Thus, the women who became pregnant during follow-up were not excluded from the data analysis. The event data used in computing the probability of presence of dysmenorrhea were, respectively, the end of GnRH-a treatment in the buserelin acetate group and the date of randomization for the expectant management group, and the date of recurrence of the pain symptom. RESULTS No significant differences were observed between the two groups in the patient's characteristics. All the patients allocated to the buserelin acetate group completed the 6 months of treatment. Amenorrhea occurred in all cases starting from the nd month. Seventeen women (89%) reported hot flushes, 6 (%) vaginal dryness, and 4 (%) spotting after months. During the treatment no patient had dysmenorrhea, all five with pelvic pain at admission reported complete resolution of the symptom, and of the three with deep dyspareunia initially, two had complete and one partial remission. Figure shows the pattern of dysmenorrhea during follow-up in the two groups. After months of follow-up, the actuarial dysmenorrhea recurrence rate in the active treatment group was significantly lower than that of the untreated patients (7% versus 8 %, P <.). This difference was maintained during the subsequent follow-up. Dysmenorrhea recurred in eight of the buserelin acetate-treated patients: in 6% (5/8) within months of treatment suspension and in the other 7% (/8) within 6 months. Modification of severity of dysmenorrhea in the individual subjects is reported in Tables and. A spontaneous, complete, and persistent resolution of dysmenorrhea was observed also in 9% of the patients given expectant management, and 9% reported a partial remission of the symptom. Except in one case the improvement started at the first menstruation after laparoscopy and D and C. The resolution of pelvic pain observed in five women of the buserelin acetate group during treatment persisted during the follow-up. In the control group, pelvic pain resolved spontaneously in one patient and persisted in two. At the end of follow-up, deep dyspareunia had not recurred in two of the affected women in the buserelin acetate group, but in the third the symptom returned to pretreatment levels. In two untreated patients with deep dyspareunia the symptom disappeared after laparoscopy. and D and C, whereas it remained unchanged in the other three. However, in the untreated patients with spontaneous resolution of deep dyspareunia this symptom was described as intermittent at study entry. DISCUSSION In our study buserelin acetate markedly reduced pain symptoms associated with endometriosis during the treatment and also for the following months. Vol. 59, No., March 99 Fedele et al. Buserelin acetate for endometriosis 57
3 I:..,liZSA." Table Pain Questionannaire Response Score Date of compilation: Date of last menstruation: A. Was your last menstrual period painful? If yes, which of the following applied?. You did not need analgesics. You took analgesics for <4 hours and pain improved. You had to take analgesics for >4 hours to improve pain 4. The analgesics taken were not efficacious 5. In addition to low abdominal pain you also had nausea, vomiting, headache, diarrhea, general malaise 6. You could carry out your normal daily activities as usual, including work 7. You found it difficult to fulfill your work and domestic commitments but succeeded in doing so nonetheless 8. You had to limit your work and domestic activities to essential tasks and eliminate the most arduous ones 9. You could not go to work and spent at least part of the day in bed Total I I Yes/no The line above represents the continuum of the opinion of the degree of pain. The left extremity of the line represents "no pain at all" and the right one "unbearable pain." Please rate the degree of your menstrual pain by making a mark on the line.* B. Have you had low, midline, or lateral abdominal ~qin other than during menstruation? Yes/no. You did not need analgesics. You took analgesics for <4 hours and pain improved. You had to take analgesics for >4 hours to improve pain 4. The analgesics taken were not efficacious 5. In addition to low abdominal pain you also had nausea, vomiting, headache, diarrhea, general malaise 6. You could carry out your normal daily activities as usual, including work 7. You found it difficult to fulfill your work and domestic commitments but succeeded in doing so nonetheless 8. You had to limit your work and domestic activities to essential tasks and eliminate the most arduous ones 9. You could not go to work and spent at least part of the day in bed I I The line above represents the continuum of the opinion of the degree of pain. The left extremity of the line represents "no pain at all" and the right one "unbearable pain." Please rate the degree of your menstrual pain by making a mark on the line. c. Have you had painful intercourses (not considering the pain at vaginal introitus)? Yes No * The length of the line is equal to cm. Scale values were obtained by measuring the distance from to the patient mark. However, conclusions can be drawn only for dysmenorrhea and not for pelvic pain and deep dyspareunia because the number of patients with the latter two symptoms was small. It must be underlined that we considered a group of patients whose main symptom was not pain but infertility. The use of this inclusion criterion, however, allowed us to recruit a homogeneous series and to design a study with a group of untreated controls. In our opinion, it would not have been ethical to propose expectant management for patients specifically requiring treatment for pain symptoms. Another characteristic of our study was that only patients with minimal or mild endometriosis were admitted, and, in fact, medical treatment is most indicated for these initial forms. Our patients themselves completed the questionnaire on pain symptoms. Because they are difficult to quantify, we used two different s to evaluate pain severity: a multidimensional one that gives greater emphasis to the social impact of pain symptoms and an analogue that expresses the subjective aspect of pain. Important differences were not observed between the two, thus demonstrating their consistency. Furthermore, the analogue has previously been described to have good reproducibility in pain measurement (8). Only deep dyspareunia was considered in this study; its severity 58 Fedele et al. Buserelin acetate for endometriosis Fertility and Sterility
4 ~i aa ~ :is 6 II 5 ~ at 4 8 months Figure Overall -month percent probability presence of dysmenorrhea in the buserelin acetate-treated patients (bottom) and in the expectant management group (top), respectively. was not evaluated because reporting of this symptom is too subjective and we do not know a reliable system to evaluate it. Our results pose two important questions. First, why is buserelin acetate treatment effective even after its suspension, although various studies have demonstrated that endometriotic lesions persist after the end of treatment (9-)? Second, why did a spontaneous remission of dysmenorrhea, partial or complete, occur after diagnostic laparoscopy in almost half of the women who did not receive any treatment? The persistent symptomatologic relief induced by buserelin acetate could be explained by the fact that atrophy of the ectopic endometrium induced by prolonged hypoestrogenism may change the architecture of endometriotic lesions and modify their relations with nerve fibers and surrounding vessels. The spontaneous resolution of dysmenorrhea in some of our untreated patients occurred immediately after laparoscopy, which suggests that this procedure, and especially the concomitant D and C, may have played a determinant role. The same mechanism might be responsible also for the remission of dysmenorrhea observed in some of the buserelin acetate group. In one of the untreated women, dysmenorrhea resolved spontaneously months after the diagnostic laparoscopy: in this case we can hypothesize a spontaneous regression of endometriosis lesions, a phenomenon already described by Thomas and Cooke (). A placebo effect has been reported to improve dysmenorrhea in ~% of patients treated; however, this improvement does not last for longer than months (). A placebo effect may have occurred in our treated patients, but this does not explain why pain relief persisted for over months after suspension of the therapy. Gonadotropin-releasing hormone agonists are considered very effective in the treatment of endometriosis-associated pelvic pain during the period they are administered, but it is not clear whether their therapeutic effect persists after the end of treatment. The authors of the first reports (9, 4-6) reported significantly different rates of recurrence (% to 75%) of pain symptoms after treatment suspension. A large multicenter study comparing the efficacy of nafarelin 8 and 4 ILg/d with that of danazol 8 mg/d reported that pain symptoms disappeared or persisted in mild form in most patients (7% versus 77% of those who had taken nafarelin 4 and 8 ILg/d, respectively) 6 months after the end of the treatment. Only % to % of the women reported severe pain symptoms (7). We compared treatment with buserelin acetate, ILg/d and danazol 6 mg/d. One year after completing the therapy, there was a recurrence of menstrual pain in 47% of the series; 7% of the pa- Table Modifications of Severity of Dysmenorrhea Evaluated According to Linear and Multidimensional Scales Months After the End of Buserelin Acetate Treatment Dysmenorrhea pretreatment Mild Moderate Severe Linear Multidimensional Linear Multidimensional Linear Multidimensional Dysmenorrhea at -month follow-up* Absent Mild Moderate Severe * When pregnancy occurred, it was considered the pattern of dysmenorrhea at last menstruation. Vol. 59, No., March 99 Fedele et al. Buserelin acetate for endometriosis 59
5 .. Table Modifications of Severity of Dysmenorrhea Evaluated According to Linear and Multidimensional Scales Months After Randomization in the Untreated Patients Dysmenorrhea pretreatment Mild Moderate Severe Linear Multidimensional Linear Multidimensional Linear Multidimensional Dysmenorrhea at -month follow-up' Absent Mild 4 9 Moderate 4 Severe When pregnancy occurred, it was considered the pattern of dysmenorrhea at last menstruation. tients reported a return of pelvic pain and deep dyspareunia (5). Franssen et al. (8) observed that 6 months after the end of treatment with buserelin acetate 9 Mg/d, 7 of the 9 women with dysmenorrhea at admission reported an improvement, whereas the symptom was unchanged in and worsened in two; in another woman it appeared ex novo. During the follow-up, pelvic pain became gradually more severe, reaching almost pretreatment levels after 4 months. In the study of Kennedy et al. (9) comparing nafarelin 4 Mg/d and danazol 6 mg/d, pain symptoms were improved in 64% of the patients who had taken nafarelin, returned to pretreatment levels in 6%, and worsened in % at 6 months offollowup. Venturini et al. () treated women with endometriosis with goserelin depot for 6 months, and in the 6 months after therapy suspension they observed a recurrence of dysmenorrhea in 5% of the patients, of deep dyspareunia in 7.5%, and of pelvic pain in.%. In a recent randomized double-blind study of the efficacy of leuprolide acetate depot versus placebo in the therapy of pelvic pain associated with endometriosis, Dlugi et al. () reported that 57% of the patients had a recurrence of dysmenorrhea at 6 months of follow-up, whereas one third continued to be free ofthe symptom at year. There was a recurrence of moderate or severe pelvic pain at pretreatment levels in 54 % of the affected patients within months of completing treatment. Regarding dyspareunia, 75% of the patients reported persistent relief after year. Definitive considerations cannot be based on an analysis of the numerous data reported in the literature because of differences in the characteristics of the patients recruited, disease stages, assessment of pain symptoms, and length of follow-up. Fur- thermore, only one study included a control group of patients not given an active treatment (). This was the only series in which the pain symptom was evaluated adequately, but the patient inclusion criteria and disease stages differed considerably from those in the present study. In conclusion, in infertile patients with minimal or mild endometriosis, buserelin acetate induces a remission of pain symptoms that persists after treatment suspension. This phenomenon is not easy to interpret; it is probable that the prolonged hypoestrogenism induced by GnRH-a has a persistent effect on the pathogenetic mechanisms underlying the pain symptoms, whether or not these are related to endometriosis. Acknowledgment. The authors thank Fabio Parazzini, M.D., Istituto di Ricerche Farmacologiche "M. Negri," Milano, Italy, for data management. REFERENCES. The American Fertility Society. Revised American Fertility Society classification of endometriosis: 985. Fertil Steril 985;4:5-.. Fedele L, Parazzini F, Bianchi S, Arcaini L, Candiani GB. Stage and localization of pelvic endometriosis and pain. Fertil Steril 99;5: Metzger DA, Luciano AA. Hormonal therapy of endometriosis. Obstet Gynecol Clin North Am 989;6: Fedele L, Bianchi S, Viezzoli T, Arcaini L, Candiani GB. Gestrinone versus danazol in the treatment of endometriosis. Fertil Steril989;5: Fedele L, Bianchi S, Arcaini L, Vercellini P, Candiani GB. Buserelin versus danazol in the treatment of endometriosis associated infertility. Am J Obstet Gynecol 989;6: Fedele L, Parazzini F, Radici E, Bocciolone L, Bianchi S, Bianchi C, et al. Buserelin acetate versus expectant management in the treatment of infertility associated with minimal or mild endometriosis: a randomized trial. Am J Obstet GynecoI99;66: Fedele et a. Buserelin acetate for endometriosis Fertility and Sterility
6 7. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 977;5: Revill SI, Robinson JO, Rosen M, Hogg MIJ. The reliability of a linear analogue for evaluating pain. Anesthesia 976;: Schriock E, Monroe SE, Henzl M, Jaffe RB. Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin). Fertil Steril 985;44: Steingold HA, Cedars M, Lu JKH, Randle D, Judd HL, Meldrum DR. Treatment of endometriosis with a long acting gonadotropin-releasing hormone agonist. Obstet Gynecol 987;69:4-.. Nisolle-Pochet M, Casanas-Roux F, Donnez J. Histologic study of ovarian endometriosis after hormonal therapy. Fertil Steril 988;49:4-6.. Thomas EJ, Cooke ID. Impact of gestrinone on the course of asymptomatic endometriosis. Br Med J 987;94:7-4.. Fedele L, Marchini M, Acaia B, Garagiola U, Tiengo M. Dynamics and significance of placebo response in primary dysmenorrhea. Pain 99;6: Meldrum DR, Chang RJ, Lu J, Vale W, Rivier J, Judd HL. Medical oophorectomy using a long-acting GnRH agonist: a possible new approach to the treatment of endometriosis. J Clin Endocrinol Metab 98;54: Lemay A, Maheux R, Faure N, Jean C, Fazekas ATA. Reversible hypogonadism induced by luteinizing hormone-re- leasing hormone (LH -RH) agonist (buserelin) as a new therapeutic approach for endometriosis. Fertil Steril984;4: Lemay A, Maheux R, Hout C, Blanchet J, Faure N. Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. Am J Obstet Gynecol 988;58: Henzl MR, Corson SL, Moghissi K, Buttram VC, Berquist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis. N Engl J Med 988;8: Franssen AMHW, Kauer FM, Chadha DR, Zijlstra la, Rolland R. Endometriosis: treatment with gonadotropin-releasing hormone buserelin. Fertil Steril989;5: Kennedy SH, Williams la, Brodribb J, Barlow DH, Shaw RW. A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertil Steril99;5: Venturini PL, Fasce V, Costantini S, Anserini P, Cucuccio S, De Cecco L. Treatment of endometriosis with goserelin depot, a long-acting gonadotropin-releasing hormone agonist analog: endocrine and clinical results. Fertil Steril 99;54: -7.. Dlugi AM, Miller JD, Knittle J, Lupron Study Group. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Fertil Steril 99;54:49-7. Vol. 59, No., March 99 Fedele et ai. Buserelin acetate for endometriosis 5
Key Words: Endometriosis, GnRH-a, goserelin, Zoladex, estrogen, sex-steroid add-back therapy,
FERTLTY AND STERLTY Copyright 1995 American Society for Reproductive Medicine Vol. 64, No. 5, November 1995 Printed on acid free paper in U. S. A. Comparison of the gonadotropin-releasing hormone agonist
More informationGoserelin (Zoladex*) depot in the treatment of endometriosist
FERTILITY AND STERILITY Copyright 1992 The American Fertility Society Printed on acid-free paper in U.S.A. Goserelin (Zoladex*) depot in the treatment of endometriosist Romeo P. Reichel, M.D.* Karl-W.
More informationThe Use of GnRH Agonists in the Treatment of Endometriomas With or Without Drainage
The Use of GnRH Agonists in the Treatment of Endometriomas With or Without Drainage Pages with reference to book, From 30 To 32 Sertac Batioglu, Havva Celikkanat, Mustafa Ugur, Leyla Mollamahmutoglu, Huseyin
More informationDepartment of Obstetrics and Gynaecology, Royal Surrey County Hospital, Guildford, United Kingdom
FERTILITY AND STERILITY Vol. 62, No.4, October 1994 Copyright c 1994 The American Fertility Society Printed on acid-free paper in U. S. A. Prospective, randomized, double-blind, controlled trial of laser
More informationLaparoscopic excision of recurrent endometriomas: long-term outcome and comparison with primary surgery
Laparoscopic excision of recurrent endometriomas: long-term outcome and comparison with primary surgery Luigi Fedele, M.D., a Stefano Bianchi, M.D., a Giovanni Zanconato, M.D., c Nicola Berlanda, M.D.,
More informationCY Tse, AMK Chow, SCS Chan. Introduction
Effects of an extended-interval dosing regimen of triptorelin depot on the hormonal profile of patients with endometriosis: prospective observational study CY Tse, AMK Chow, SCS Chan Objective. To evaluate
More informationClinica Ostetrica e Ginecologica I, Istituto Luigi Mangiagalli, University of Milano, Milan, Italy
FERTILITY AND STERILITY VOL. 80, NO. 2, AUGUST 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Comparison of a levonorgestrel-releasing
More informationEndometriosis: treatment with gonadotropinreleasing hormone agonist Buserelin*t
FERTILITY AND STERILITY Copyright 989 The American Fertility Society Printed in U.S.A. Endometriosis: treatment with gonadotropinreleasing hormone agonist Buserelin*t Anton M. H. W. Franssen, M.D.:j: Frank
More informationA Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis
SH SUEN & SCS CHAN A Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis Sik Hung SUEN MBChB, MRCOG Resident
More informationEndometriosis-associated pelvic pain: evidence for an association between the stage of disease and a history of chronic pelvic pain*
F ERTILITY AND STERILITY Copyright " 1997 American Society for Reproductive Medicine Published by Elsevier Science Inc. Vo!. 68, No. 1, J uly 1997 Printed on acid -free paper in U. S. A. Endometriosis-associated
More informationIs the endometriosis recurrence rate increased after ovarian hyperstimulation?
Is the endometriosis recurrence rate increased after ovarian hyperstimulation? Thomas M. D Hooghe, M.D., Ph.D., Bénédicte Denys, M.D., Carl Spiessens, Ph.D., Christel Meuleman, M.D., and Sophie Debrock,
More informationLaparoscopic uterosacral ligament resection for dysmenorrhea associated with endometriosis: results of a randomized, controlled trial
FERTILITY AND STERILITY VOL. 80, NO. 2, AUGUST 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Laparoscopic uterosacral ligament
More informationGnRH agonist and antagonist: Options for endometriosis pain treatment
Thomas Jefferson University Jefferson Digital Commons Department of Obstetrics and Gynecology Faculty Papers Department of Obstetrics and Gynecology November 2006 GnRH agonist and antagonist: Options for
More informationCritical Appraisal of Endometriosis Management for Pain and Subfertility
Critical Appraisal of Endometriosis Management for Pain and Subfertility N. F. Zuberi,J. H. Rizvi ( Department of Obstetrics and Gynaecology, The Aga Khan University, Karachi. ) Introduction Endometriosis
More informationTreatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy*
Gynecology-endocrinology FERTILITY AND STERILITY Copyright 1994 The American Fertility Society Printed on acid-free paper in U S. A. Treatment of hirsutism with a gonadotropin-releasing hormone agonist
More informationMANAGEMENT OF REFRACTORY ENDOMETRIOSIS
(339) MANAGEMENT OF REFRACTORY ENDOMETRIOSIS Serdar Bulun, MD JJ Sciarra Professor and Chair Department of Ob/Gyn Northwestern University ENDOMETRIOSIS OCs Teenager: severe dysmenorrhea often starting
More informationLaparoscopy and Endometriosis: Preventing Complications and Improving Outcomes. Luis C. Paez M.D.
Laparoscopy and Endometriosis: Preventing Complications and Improving Outcomes Luis C. Paez M.D. Assumptions Pelvic pain Not desiring immediate fertility H & P suggest endometriosis OC/NSAID failures Endo
More informationDepartment of Gynecologic Surgery, Maternité Jeanne de Flandres, Lille, France
FERTILITY AND STERILITY VOL. 77, NO. 4, APRIL 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Dienogest is as effective
More informationPre and post surgical medical therapy. Mauro Busacca M.D. Dept of Obstetrics and Gynecology University of Milan- Italy
Pre and post surgical medical therapy Mauro Busacca M.D. Dept of Obstetrics and Gynecology University of Milan- Italy introduction A disease is an open problem when two conditions are nor satisfied: The
More informationHormonal and biochemical changes during treatment of endometriosis with the luteinizing hormone-releasing
FERTILITY AND STERILITY Copyright" 199 The American Fertility Society Vol. 54, No.2, August 199 Printed on acid-free paper in U.S.A. Hormonal and biochemical changes during treatment of endometriosis with
More informationEndometriosis Treatment & Management Medscape
Endometriosis Treatment & Management Medscape Updated: Apr 25, 2016 Author: G Willy Davila, MD; Chief Editor: Michel E Rivlin, MD more... Approach Considerations The dependence of endometriosis on the
More informationORILISSA (elagolix) oral tablet
ORILISSA (elagolix) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationEndometriosis. *Chocolate cyst in the ovary
Endometriosis What is endometriosis? Endometriosis is a common condition in young women. It's chronic, painful, and it often progressively gets worse over the time. *Chocolate cyst in the ovary Normally,
More informationSurgical treatment of deep endometriosis and risk of recurrence
Journal of Minimally Invasive Gynecology (2005) 12, 508-513 Surgical treatment of deep endometriosis and risk of recurrence Michele Vignali, MD, Stefano Bianchi, MD, Massimo Candiani, MD, Giovanna Spadaccini,
More informationDienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis
doi:10.1111/jog.13023 J. Obstet. Gynaecol. Res. Vol. 42, No. 9: 1152 1158, September 2016 Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis Yotaro
More informationResults of implication of aromatase inhibitors in therapy of genital endometriosis Yarmolinskaya M. (Speaker), Bezhenar V., Molotkov A.
Results of implication of aromatase inhibitors in therapy of genital endometriosis Yarmolinskaya M. (Speaker), Bezhenar V., Molotkov A. Ott's Research Institute of Obstetrics, Gynecology and Reproductology,
More informationD-Trp-6-luteinizing hormone-releasing hormone microcapsules in the treatment of uterine leiomyomas
FERTILITY AND STERILITY Copyright" '1989 The American Fertility Society Vol. 52, No.3, Septemher 1989 Printed on acid-free paper in U.S.A. D-Trp-6-luteinizing hormone-releasing hormone microcapsules in
More informationValidation study of nonsurgical diagnosis of endometriosis
FERTILITY AND STERILITY VOL. 76, NO. 5, NOVEMBER 2001 Copyright 2001 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Validation study
More informationPalm Beach Obstetrics & Gynecology, PA
Palm Beach Obstetrics & Gynecology, PA 4671 S. Congress Avenue, Lake Worth, FL 33461 561.434.0111 4631 N. Congress Avenue, Suite 102, West Palm Beach, FL 33407 Endometriosis The lining of the uterus is
More informationAssisted Reproductive Technology (ART) / Infertility / Synarel (nafarelin)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.03 Subject: Synarel Page: 1 of 5 Last Review Date: September 15, 2016 Synarel Description Assisted
More informationChapter 3. Renato Seracchioli Mohamed Mabrouk Clarissa Frascà Linda Manuzzi Luca Savelli Stefano Venturoli Fertil Steril Jul; 94(2):
Chapter 3 Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial Renato Seracchioli Mohamed Mabrouk Clarissa
More informationEndometriosis Samuel J. Chantilis, M.D.
Endometriosis Samuel J. Chantilis, M.D. I. INTRODUCTION Endometriosis is the presence and growth of glands and stroma identical to the lining of the uterus in an aberrant location. Common symptoms of endometriosis
More informationt Funded by a grant from TAP Pharmaceuticals, Deerfield, Illinois.
FERTILITY AND STERILITY Vol. 63, No.4, April 1995 Copyright 1995 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Prolonged gonadotropin-releasing hormone agonist treatment
More informationEndometriosis. Assoc.Prof.Pawin Puapornpong, Faculty of Medicine, Srinakharinwirot University.
Endometriosis Assoc.Prof.Pawin Puapornpong, Faculty of Medicine, Srinakharinwirot University. Endometriosis Definition: Ectopic Endometrial Tissue True Incidence Unknown:? 1-5% Does NOT Discriminate by
More informationThe effect of gonadotropin-releasing hormone agonist on thyroid-stimulating hormone and prolactin secretion in adult premenopausal women
FERTILITY AND STERILITY Vol. 64, No.4, October 1995 Copyright 1995 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. The effect of gonadotropin-releasing hormone agonist
More informationThis case represents 1 of the challenges of
OBG MANAGEMENT BY DAVID ADAMSON, MD Minimal to mild endometriosis: 4 treatment options Since even limited disease can cause infertility or substantial pain, it should be taken as seriously as severe endometriosis.
More informationHistologic study of peritoneal endometriosis in infertile women
FERTILITY AND STERILITY Copyright" 1990 The American Fertility Society Printed on acid-free paper in U.S.A. Histologic study of peritoneal endometriosis in infertile women Michelle Nisolle, M.D. Benedicte
More informationunderstanding endometriosis Authored by Dr KT Subrayen Sponsored by
understanding endometriosis Authored by Dr KT Subrayen Sponsored by in this booklet What is Endometriosis? 1 What causes Endometriosis? 3 What does Endometriosis look like? 4 Common symptoms of Endometriosis
More informationNeodymium: VAG laser hysteroscopy in large submucous fibroids
FERTILITY AND STERILITY Copyright 1990 The American Fertility Society Printed on acid-free paper in U.S.A. Neodymium: VAG laser hysteroscopy in large submucous fibroids Jacques Donnez, M.D., Ph.D.*
More informationEndometriosis Information Leaflet
Endometriosis Information Leaflet What is Endometriosis? Endometriosis is a condition where tissue similar to the lining of the womb (endometrium) is found outside the womb. About 1 out of 10 women of
More informationEndometriosis. What you need to know. 139 Dumaresq Street Campbelltown Phone Fax
Endometriosis What you need to know 139 Dumaresq Street Campbelltown Phone 4628 5292 Fax 4628 0349 www.nureva.com.au September 2015 What is Endometriosis? Endometriosis is a condition whereby the lining
More informationGonadotropin-releasing hormone agonist treatment before abdominal myomectomy: a controlled trial
FERTILITY AND STERILITY VOL. 79, NO. 6, JUNE 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Gonadotropin-releasing hormone
More informationPregnancy Outcome following Active Management of Endometriosis after Laparoscopy in Infertile Women A Prospective Cohort Study
ORIGINAL RESEARCH KERALA MEDICAL JOURNAL Pregnancy Outcome following Active Management of Endometriosis after Laparoscopy in Infertile Women A Prospective Cohort Study Anupama R KJK Hospital, Nalanchira,
More informationAn evidence-based medicine approach to the treatment of endometriosis-associated chronic pelvic pain: placebo-controlled studies Howard F M
An evidence-based medicine approach to the treatment of endometriosis-associated chronic pelvic pain: placebo-controlled studies Howard F M Authors' objectives To assess the efficacy of treatment of endometriosis-associated
More informationHenk R. Franke, M.D., Ph.D., a Peter H. M. van de Weijer, M.D., Ph.D., b Ton M. M. Pennings, M.D., c and Marius J. van der Mooren, M.D., Ph.D.
FERTILITY AND STERILITY VOL. 74, NO. 3, SEPTEMBER 2000 Copyright 2000 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Gonadotropin-releasing
More informationRenato Seracchioli, M.D., Mohamed Mabrouk, M.D., Clarissa Frasca, M.D., Linda Manuzzi, M.D., Luca Savelli, M.D., and Stefano Venturoli, M.D.
Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial Renato Seracchioli, M.D., Mohamed Mabrouk, M.D.,
More informationEndometriosis and Infertility - FAQs
Published on: 8 Apr 2013 Endometriosis and Infertility - FAQs Introduction The inner lining of the uterus is called the endometrium and it responds to changes that take place during a woman's monthly menstrual
More informationEvidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors.
Evidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors. Who needs surveillance? Chiarelli et al. Early menopause and Infertility
More informationGonadotropin Releasing Hormone (GnRH) Analogs Drug Class Prior Authorization Protocol
Gonadotropin Releasing Hormone (GnRH) Analogs Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been
More informationSurgical treatment of endometriosis: location and patterns of disease at reoperation
Surgical treatment of endometriosis: location and patterns of disease at reoperation Elizabeth Taylor, M.D., and Christina Williams, M.D. Division of Reproductive Endocrinology and Infertility, Department
More informationDepartment of Obstetrics and Gynecology, Chosun University School of Medicine, Gwangju, Korea
J MM pissn: 2288-6478, eissn: 2288-6761 Journal of Menopausal Medicine 2016;22:174-179 Original Article Raloxifene Administration in Women Treated with Long Term Gonadotropin-releasing Hormone Agonist
More informationOrilissa (elagolix) NEW PRODUCT SLIDESHOW
Orilissa (elagolix) NEW PRODUCT SLIDESHOW Introduction Brand name: Orilissa Generic name: Elagolix Pharmacological class: GnRH antagonist Strength and Formulation: 150mg, 200mg; tabs Manufacturer: AbbVie
More informationAddressing Endometriosis with Your Patients: Combining Individualized Treatment Options with Patient-Clinician Dialogue
Addressing Endometriosis with Your Patients: Combining Individualized Treatment Options with Patient-Clinician Dialogue Objectives Describe the multiple symptoms of endometriosis and its varied presentation
More informationInt J Clin Exp Med 2013;6(7): /ISSN: /IJCEM Yi Han 1,2, Shi-En Zou 1, Qi-Qi Long 1, Shao-Fen Zhang 1
Int J Clin Exp Med 2013;6(7):583-588 www.ijcem.com /ISSN:1940-5901/IJCEM1306010 Original Article The incidence and characteristics of uterine bleeding during postoperative GnRH agonist treatment combined
More informationSurgical management of peritoneal endometriosis. GKS koulutuspäivät Jaana Fraser PKSSK
Surgical management of peritoneal endometriosis GKS koulutuspäivät 24.9.2009 Jaana Fraser PKSSK Peritoneal endometriosis Tumor-like small lesions, located on the surface of peritoneum Diameter some millimeters
More informationSmita Jain, M.B., M.S.* and Maureen E. Dalton, F.R.C.O.G. Sunderland Royal Hospital, Sunderland, Tyne and Wear, United Kingdom
ENDOMETRIOSIS FERTILITY AND STERILITY VOL. 72, NO. 5, NOVEMBER 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Chocolate
More informationDrug Class Update: Drugs for Endometriosis
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596
More informationDrug Class Monograph
Drug Class Monograph Class: Gonadotropin Releasing Hormone (GnRH) Analogs Drugs: Eligard (leuprolide acetate), Firmagon (degarelix), Lupaneta Pack (leuprolide acetate and norethindrone), Lupron Depot (leuprolide
More informationInt J Clin Exp Med 2016;9(10): /ISSN: /IJCEM
Int J Clin Exp Med 2016;9(10):19935-19943 www.ijcem.com /ISSN:1940-5901/IJCEM0027833 Original Article Clinical outcome of various regimens of gonadotropin-releasing hormone analogues after conservative
More informationSurgical Management of Endometriosis associated Infertility
Surgical Management of Endometriosis associated Infertility Dr. Ingrid Lok Specialist in Obstetrics and Gynaecology (Honorary Clinical Associate Professor, CUHK) HA commission training 24.2.2014 Endometriosis
More informationCLEAR COVERAGE HYSTERECTOMY CHECKLISTS
CLEAR COVERAGE HYSTERECTOMY CHECKLISTS Click on the link below to access the checklist sheet. Abnormal Uterine Bleeding Adenomyosis Chronic Abdominal or Pelvic Pain Endometriosis Fibroids General Guidelines
More information2.0 Synopsis. Lupron Depot M Clinical Study Report R&D/09/093. (For National Authority Use Only) to Part of Dossier: Name of Study Drug:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: Name of Study Drug: Volume: Abbott-43818 (ABT-818) leuprolide acetate for depot suspension (Lupron Depot ) Name of
More informationTheFormationofaScoringSystemtoDiagnoseEndometriosis. The Formation of a Scoring System to Diagnose Endometriosis
Global Journal of Medical Research: E Gynecology and Obstetrics Volume 18 Issue 1 Version 1.0 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Online ISSN: 49-4618
More informationMenstrual cyclicity of CA-125 in patients with endometriosis*t*
FERTILITY AND STERILITY Copyright 1992 The American Fertility Society Printed on acid-free paper in U.S.A. Menstrual cyclicity of CA-125 in patients with endometriosis*t* Mark D. Hornstein, M.D. II Phaedra
More informationme LUTEINIZED UNRUPTURED FOLLICLE SYNDROME AND ENDOMETRIOSIS
FERTILITY AND STERILITY Copyright c 980 The American Fertility Society Vol. 33,, JanuaEY 980 Printed in U.S.A. me LUTEINIZED UNRUPTURED FOLLICLE SYNDROME AND ENDOMETRIOSIS W. PAULDMOWSKI, M.D.,.PH.D.*
More informationResearch Article. Comparative analysis of Yoga and clomiphene in infertile women. Richa Sharma 1, Himsweta Shrivastava 1, Arvind Kumar 2
Research Article Comparative analysis of Yoga and clomiphene in infertile women Richa Sharma 1, Himsweta Shrivastava 1, Arvind Kumar 2 1 Department of Obstetrics & Gynecology, University College of Medical
More informationLong-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial
Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial Renato Seracchioli, M.D., Mohamed Mabrouk, M.D., Clarissa Frasca, M.D., Linda Manuzzi,
More informationEndometriosis, pelvic pain, and psychological functioning
FERTILITY AND STERILITY Vol. 63. No.4. April 1995 Copyright 1995 American Society for Reproductive Medicine Printed on acid-free paper in U. s. A. Endometriosis, pelvic pain, and psychological functioning
More informationGynecology-endocrinology
Gynecology-endocrinology FERTILITY AND STERILITY Vol. 64, No.3, September 1995 Copyright C> 1995 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Gonadotropin-releasing
More informationPRESACRAL NEURECTOMY AND UTERINE NERVE ABLATION FOR PELVIC PAIN
PRESACRAL NEURECTOMY AND UTERINE NERVE ABLATION FOR PELVIC PAIN Protocol: PAI008 Effective Date: November 1, 2015 Table of Contents Page COMMERCIAL, MEDICARE & MEDICAID COVERAGE RATIONALE... 1 DESCRIPTION
More informationThe significance of lymphocytic-leukocytic infiltrates in interpreting late luteal phase endometrial biopsies
FERTILITY AND STERILITY Copyright 1982 The American Fertility Society Vol. 37, No. 6, June 1982 Printed in U.S A. The significance of lymphocytic-leukocytic infiltrates in interpreting late luteal phase
More informationFrequency of menses. Duration of menses 3 days to 7 days. Flow/amount of menses Average blood loss with menstruation is 60-80cc.
Frequency of menses 24 days (0.5%) to 35 days (0.9%) Age 25, 40% are between 25 and 28 days Age 25-35, 60% are between 25 and 28 days Teens and women over 40 s cycles may be longer apart Duration of menses
More informationPRESACRAL NEURECTOMY AND UTERINE NERVE ABLATION FOR PELVIC PAIN
MEDICAL POLICY PRESACRAL NEURECTOMY AND UTERINE NERVE ABLATION FOR PELVIC PAIN Policy Number: 2014T0059K Effective Date: October 1, 2014 Table of Contents BENEFIT CONSIDERATIONS COVERAGE RATIONALE APPLICABLE
More informationClinical Policy: Goserelin Acetate (Zoladex) Reference Number: CP.PHAR.171 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 10.01.16 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More informationEndometriosis and infertility
Endometriosis and infertility The Practice Committee of the American Society for Reproductive Medicine Birmingham, Alabama Women with endometriosis typically present with pelvic pain, infertility or an
More informationLaparoscopic endometriosis treatment: is it better?*
FERTILITY AND STERILITY Copyright 1993 The American Fertility Society Selected paper from 1991 Pacific Coast Society Meeting Printed on acid-free paper in U.S.A. Laparoscopic endometriosis treatment: is
More informationHysteroscopic Endometrial Destruction, Optimum Method for Preoperative Endometrial Preparation: A Prospective, Randomized, Multicenter Evaluation
SCIENTIFIC PAPER Hysteroscopic Endometrial Destruction, Optimum Method for Preoperative Endometrial Preparation: A Prospective, Randomized, Multicenter Evaluation O. Shawki, MD, A. Peters, DO, S. Abraham-Hebert,
More informationM0BCore Safety Profile. Active substance: Triptorelin Pharmaceutical form(s)/strength: 0,1 mg P-RMS: DE/H/PSUR/0038/002 Date of FAR:
M0BCore Safety Profile Active substance: Triptorelin Pharmaceutical form(s)/strength: 0,1 mg P-RMS: DE/H/PSUR/0038/002 Date of FAR: 26.05.2014 4.3 Contraindications Hypersensitivity to GnRH, its analogues
More informationKey words: polycystic ovary syndrome, hypothalmic-pituitary-ovarian axes
Clin Pediatr Endocrinol 1999; 8(2), 77-84 Copyright 1999 by The Japanese Society for Pediatric Endocrinology Clinical, Hormonal, and Radiological Studies at Baseline, During and After Long Term GnRH Analog
More informationLUTEINIZED UNRUPTURED FOLLICLE SYNDROME: A SUBTLE CAUSE OF INFERTILITY*
FERTILITY AND STERILITY Copyright c 1978 The American Fertility Society Vol. 29, No.3, March 1978 Printed in U.S.A. LUTEINIZED UNRUPTURED FOLLICLE SYNDROME: A SUBTLE CAUSE OF INFERTILITY* JAROSLA V MARIK,
More information10/16/2014. Adolescents (ages 10 19) and young adults (ages 20 24) together compose about 21% of the population of the United States.
The purview of pediatrics includes the growth, development, and health of the child and therefore begins in the period before birth when conception is apparent. It continues through childhood and adolescence
More informationCigna Medical Coverage Policy
Cigna Medical Coverage Policy Subject Pelvic Denervation Procedures Table of Contents Coverage Policy... 1 General Background... 1 Coding/Billing Information... 4 References... 4 Effective Date... 6/15/2014
More informationPublic Statement: Medical Policy Statement: Background:
ARBenefits Approval: 10/12/2011 Effective Date: 01/01/2012 Revision Date: Code(s): 58578, unlisted laparoscopy procedure, uterus Medical Policy Title: Surgical Interruption of Pelvic Nerve Pathways for
More informationThe pharmacological management of ENDOMETRIOSIS
The pharmacological management of ENDOMETRIOSIS 18 Endometriosis is a gynaecological condition in which endometrial tissue is present outside the uterine cavity, causing cyclic symptoms and, often, reduced
More informationhttps://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm
Journal Article Version This is the publisher s version. This version is defined in the NISO recommended practice RP-8-2008 http://www.niso.org/publications/rp/ Suggested Reference Brown, J., & Farquhar,
More informationDoes Helica treatment of early endometriosis confer short- and long-term benefits in terms of pain relief and sub-fertility?
Gynecol Surg (2013) 10:213 217 DOI 10.1007/s10397-013-0803-7 ORIGINAL ARTICLE Does Helica treatment of early endometriosis confer short- and long-term benefits in terms of pain relief and sub-fertility?
More informationUse of Ovarian Suppression and Ablation in Breast Cancer Treatment
Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation
More informationSurgical Interruption of Pelvic Nerve Pathways for Primary and Secondary Dysmenorrhea
Page: 1 of 7 Last Review Status/Date: June 2015 for Primary and Secondary Dysmenorrhea Description Two laparoscopic surgical approaches are proposed as adjuncts to conservative surgical therapy for the
More informationENDOSCOPIC MANAGEMENT OF A URETERAL OBSTRUCTION CAUSED BY ENDOMETRIOSIS: A CASE REPORT
ENDOSCOPIC MANAGEMENT OF A URETERAL OBSTRUCTION CAUSED BY ENDOMETRIOSIS: A CASE REPORT Hsu-Cheng Juan, 1 Hsin-Chih Yeh, 1 Hsi-Lin Hsiao, 1 Shean-Fang Yang, 2 and Wen-Jeng Wu 1,3 Departments of 1 Urology
More informationCNGOF Guidelines for the Management of Endometriosis
CNGOF Guidelines for the Management of Endometriosis Anatomoclinical forms of endometriosis Definitions Endometriosis is defined as the presence of endometrial tissue containing both glands and stroma
More informationEndometriosis and infertility
FERTILITY AND STERILITY VOL. 81, NO. 5, MAY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Endometriosis and infertility
More informationDIAGNOSIS OF ENDOMETRIOSIS
,,,,,,,,,,,,,,,,,,,,,,,, Chapter 5 DIAGNOSIS OF ENDOMETRIOSIS This section will review the evidence for the different methods used to make a correct diagnosis of endometriosis. While there may be confusion
More informationEVALUATION OF WOMEN FOLLOWING HYSTERECTOMY WITH AND WITHOUT CONSERVATION OF OVARIES
Int. J. Chem. Sci.: 6(3), 2008, 1228-1235 EVALUATION OF WOMEN FOLLOWING HYSTERECTOMY WITH AND WITHOUT CONSERVATION OF OVARIES RAMPRASAD DEY, SUBHASH CHANDRA BISWAS, RANU ROY BISWAS a and ARUNIMA MUKHOPADHYAY
More informationLeuprolide Acetate for Injection mg (Depot) LUPRODEX TM (DEPOT)
For the use only of Physician, Gynaecologist, Oncologist, Endocrinologist, Hospital or Laboratory Leuprolide Acetate for Injection 11.25 mg (Depot) LUPRODEX TM (DEPOT) 11.25 mg (3 months Depot) Lyophilized
More informationNon-contraceptive Uses of the Levonorgestrel Intrauterine Device Elena Gates, MD http://www.mirena-us.com/pvs1/pri/whatisframe.html Progestin levels with LNG- IUS Lower plasma levels Mirena 150-200 pg/ml
More informationWhat is the most important information I should know about goserelin? What should I discuss with my healthcare provider before receiving goserelin?
1 of 5 6/10/2016 4:04 PM Generic Name: goserelin (implant) (GOE se REL in) Brand Name: Zoladex What is goserelin? Goserelin is a man-made form of a hormone that regulates many processes in the body. Goserelin
More informationSummary A LOOK AT ELAGOLIX FOR ENDOMETRIOSIS JULY 2018
JULY 2018 WHAT IS ENDOMETRIOSIS? Endometriosis is a chronic gynecological condition with symptoms that include painful menstrual periods, nonmenstrual pelvic pain, and pain during intercourse, as well
More informationLaparoscopic cautery in the treatment of endometriosis-related infertility
4 4 FERTILITY AND STERILITY Copyright ID 1991 The American Fertility Society Printed on acid-free paper in U.S.A. Laparoscopic cautery in the treatment of endometriosis-related infertility Ana A. Murphy,
More informationUterine-Sparing Treatment Options for Symptomatic Uterine Fibroids
Uterine-Sparing Treatment Options for Symptomatic Uterine Fibroids Developed in collaboration Learning Objective Upon completion, participants should be able to: Review uterine-sparing fibroid therapies
More informationEndometriosis. A Guide for Patients PATIENT INFORMATION SERIES
Endometriosis A Guide for Patients PATIENT INFORMATION SERIES Published by the American Society for Reproductive Medicine under the direction of the Patient Education Committee and the Publications Committee.
More information